



<http://www.interfacebiologics.com/>

Interface Biologics develops transformative biomedical polymer technologies that enhance the safety and effectiveness of implantable medical devices by reducing thrombosis, inhibiting infection and providing programmable delivery of pharmaceuticals.

Founded in 2001, Interface Biologics Inc. is a spin out from the University of Toronto and the ground breaking work of Professor Paul Santerre, who continues to be actively involved in the company as Chief Scientific Officer.

IBI has raised over \$30M in venture capital financing from the Business Development Bank of Canada (BDC), Covington Venture Partners, the MaRS Investment Accelerator Fund and DSM Venturing.

Covington, through affiliated funds, first invested in IBI in 2001 and has invested in excess of \$14 million into the Company since that time and maintains a significant voting interest in the Company.